Managing Type 2 Diabetes with Dual-Action Therapies: The Empasug Range by Intra Life Pharma

 Apr 21, 2025

Managing Type 2 Diabetes Mellitus (T2DM) requires more than just glycaemic control—it demands personalised care built on science-backed therapies. With over two decades of experience in pharmaceutical innovation, Intra Life Pharma has established itself as a trusted name among healthcare professionals and institutions across India. Our Empasug range brings together dual-action therapies designed to improve patient outcomes and simplify diabetes management.

Let’s explore how each formulation within this range supports effective, evidence-based diabetes care.

Backed by Clinical Research and Expert Formulation

Each product in the Empasug range is developed using clinically approved molecules recommended in national and international diabetes management guidelines. Our in-house medical affairs and R&D teams, with expertise in endocrinology and pharmacology, ensure that every combination meets therapeutic efficacy, safety, and compliance standards.

Empasug -M 500/12.5

Combination: Empasug -M 500/12.5 — Empagliflozin 12.5 mg + Metformin 500 mg

This fixed-dose combination addresses two major defects in T2DM—insulin resistance and renal glucose reabsorption.

• Reduces fasting and post-meal glucose levels

• Enhances insulin sensitivity

• Complements diet and exercise

Recommended by physicians for newly diagnosed as well as uncontrolled diabetic patients, this combination is accessible via authorised dealers and distributors across India.

Empasug-LG 25mg

Combination: Empasug-LG 25mg — Empagliflozin 25 mg + Linagliptin 5 mg

This dual-acting formula combines an SGLT2 inhibitor with a DPP-4 inhibitor for a more potent and synergistic control of blood glucose levels.

• Clinically proven to reduce HbA1c

• Low risk of hypoglycemia

• Supports weight loss and metabolic balance

Ideal for patients with cardiovascular risks or those needing intensified glycaemic control.

Empasug 10mg

Monotherapy: Empasug 10mg — Empagliflozin 10 mg

This monotherapy is recommended as a first-line add-on for patients intolerant to metformin or needing single-drug therapy.

• Lowers blood sugar by increasing urinary glucose excretion

• Provides added benefit in reducing heart failure risk

• Suitable for patients with early-stage kidney involvement

Intra Life Pharma, as a reputed exporter, ensures this product meets global standards of safety and quality.

Empasug ST 100/25

Combination: Empasug ST 100/25 — Sitagliptin 100 mg + Empagliflozin 25 mg

One of the most advanced fixed-dose combinations for T2DM, combining the benefits of two modern drug classes.

• Improves both fasting and postprandial glucose levels

• Promotes insulin secretion and beta-cell function

• A well-tolerated option for long-term management

Widely adopted by clinicians for patients with complex glycaemic patterns.

Empasug -M 500/5

Combination: Empasug -M 500/5 — Empagliflozin 5 mg + Metformin 500 mg

This low-dose formulation is ideal for elderly patients, those new to combination therapy, or those with sensitive glycaemic profiles.

• Mild yet effective dual-action

• Reduces treatment-related adverse effects

• Initiates therapy with better tolerance

Used commonly in OPD setups, this formulation is available through certified dealers and retailers nationwide.

Why Healthcare Professionals Trust Intra Life Pharma

With a deep-rooted presence in the Indian pharmaceutical ecosystem, Intra Life Pharma is trusted by over 75,000+ healthcare providers. Our operations span across 28 states, with stringent quality control protocols and WHO-GMP-certified manufacturing facilities.

We ensure:

• 100% authentic, traceable medicines

• Scientifically supported combinations

• Prompt delivery and responsive customer support

Whether you’re a hospital, pharmacy, or health franchise looking for a reliable manufacturer or supplier, Intra Life Pharma is your preferred partner in diabetes care.